These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 29369162)

  • 1. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.
    Mulligan N; Best BM; Wang J; Capparelli EV; Stek A; Barr E; Buschur SL; Acosta EP; Smith E; Chakhtoura N; Burchett S; Mirochnick M;
    AIDS; 2018 Mar; 32(6):729-737. PubMed ID: 29369162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
    Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
    PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV.
    Momper JD; Best BM; Wang J; Capparelli EV; Stek A; Barr E; Badell ML; Acosta EP; Purswani M; Smith E; Chakhtoura N; Park K; Burchett S; Shapiro DE; Mirochnick M;
    AIDS; 2018 Nov; 32(17):2507-2516. PubMed ID: 30134297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
    Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
    Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus.
    Bollen P; Freriksen J; Konopnicki D; Weizsäcker K; Hidalgo Tenorio C; Moltó J; Taylor G; Alba-Alejandre I; van Crevel R; Colbers A; Burger D;
    Clin Infect Dis; 2021 Jan; 72(1):121-127. PubMed ID: 32103260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efavirenz pharmacokinetics during pregnancy and infant washout.
    Kreitchmann R; Schalkwijk S; Best B; Wang J; Colbers A; Stek A; Shapiro D; Cressey T; Mirochnick M; Burger D
    Antivir Ther; 2019; 24(2):95-103. PubMed ID: 30530925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Atazanavir Boosted With Cobicistat in Pregnant and Postpartum Women With HIV.
    Momper JD; Wang J; Stek A; Shapiro DE; Powis KM; Paul ME; Badell ML; Browning R; Chakhtoura N; Denson K; Rungruengthanakit K; George K; Capparelli EV; Mirochnick M; Best BM;
    J Acquir Immune Defic Syndr; 2022 Mar; 89(3):303-309. PubMed ID: 34732682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
    Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
    Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.
    Nguyen B; Foisy MM; Hughes CA
    Ann Pharmacother; 2019 Aug; 53(8):833-844. PubMed ID: 30739498
    [No Abstract]   [Full Text] [Related]  

  • 10. Raltegravir pharmacokinetics during pregnancy.
    Watts DH; Stek A; Best BM; Wang J; Capparelli EV; Cressey TR; Aweeka F; Lizak P; Kreitchmann R; Burchett SK; Shapiro DE; Hawkins E; Smith E; Mirochnick M;
    J Acquir Immune Defic Syndr; 2014 Dec; 67(4):375-81. PubMed ID: 25162818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
    Malaba TR; Nakatudde I; Kintu K; Colbers A; Chen T; Reynolds H; Read L; Read J; Stemmet LA; Mrubata M; Byrne K; Seden K; Twimukye A; Theunissen H; Hodel EM; Chiong J; Hu NC; Burger D; Wang D; Byamugisha J; Alhassan Y; Bokako S; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
    Lancet HIV; 2022 Aug; 9(8):e534-e543. PubMed ID: 35905752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.
    Ruel TD; Acosta EP; Liu JP; Gray KP; George K; Montañez N; Popson S; Buchanan AM; Bartlett M; Dayton D; Anthony P; Brothers C; Vavro C; Singh R; Koech L; Vhembo T; Mmbaga BT; Pinto JA; Dobbels EFM; Archary M; Chokephaibulkit K; Ounchanum P; Deville JG; Hazra R; Townley E; Wiznia A;
    Lancet HIV; 2022 May; 9(5):e332-e340. PubMed ID: 35489377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093.
    Viani RM; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Steimers D; Min S; Wiznia A;
    Pediatr Infect Dis J; 2015 Nov; 34(11):1207-13. PubMed ID: 26244832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.
    Tran AH; Best BM; Stek A; Wang J; Capparelli EV; Burchett SK; Kreitchmann R; Rungruengthanakit K; George K; Cressey TR; Chakhtoura N; Smith E; Shapiro DE; Mirochnick M;
    J Acquir Immune Defic Syndr; 2016 Jul; 72(3):289-96. PubMed ID: 26918544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV.
    Momper JD; Wang J; Stek A; Shapiro DE; Scott GB; Paul ME; Febo IL; Burchett S; Smith E; Chakhtoura N; Denson K; Rungruengthanakit K; George K; Yang DZ; Capparelli EV; Mirochnick M; Best BM;
    AIDS; 2021 Jul; 35(8):1191-1199. PubMed ID: 34076612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing.
    Greener BN; Patterson KB; Prince HM; Sykes CS; Adams JL; Dumond JB; Shaheen NJ; Madanick RD; Dellon ES; Cohen MS; Kashuba AD
    J Acquir Immune Defic Syndr; 2013 Sep; 64(1):39-44. PubMed ID: 23945251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1.
    Dickinson L; Walimbwa S; Singh Y; Kaboggoza J; Kintu K; Sihlangu M; Coombs JA; Malaba TR; Byamugisha J; Pertinez H; Amara A; Gini J; Else L; Heiberg C; Hodel EM; Reynolds H; Myer L; Waitt C; Khoo S; Lamorde M; Orrell C;
    Clin Infect Dis; 2021 Sep; 73(5):e1200-e1207. PubMed ID: 33346335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing.
    Lewis JM; Railton E; Riordan A; Khoo S; Chaponda M
    AIDS; 2016 May; 30(8):1313-5. PubMed ID: 27128333
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics of tenofovir during pregnancy and postpartum.
    Best BM; Burchett S; Li H; Stek A; Hu C; Wang J; Hawkins E; Byroads M; Watts DH; Smith E; Fletcher CV; Capparelli EV; Mirochnick M;
    HIV Med; 2015 Sep; 16(8):502-11. PubMed ID: 25959631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
    Turkova A; Waalewijn H; Chan MK; Bollen PDJ; Bwakura-Dangarembizi MF; Kekitiinwa AR; Cotton MF; Lugemwa A; Variava E; Ahimbisibwe GM; Srirompotong U; Mumbiro V; Amuge P; Zuidewind P; Ali S; Kityo CM; Archary M; Ferrand RA; Violari A; Gibb DM; Burger DM; Ford D; Colbers A;
    Lancet HIV; 2022 Sep; 9(9):e627-e637. PubMed ID: 35868341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.